Table 1. Baseline Characteristics of the Patientsa.
| Variable | Garlic Group (n = 27) | Placebo Group (n = 29) | P |
|---|---|---|---|
| Age, y | 56.88 ± 1.67 | 61.68 ± 1.85 | 0.06 |
| Sex, male, (%) | 74.1 | 79.3 | 0.65 |
| Body Weight, Kg | 74.70 ± 2.94 | 69.75 ± 2.0 | 0.16 |
| BMI, kg/m 2 | 26.09 ± 0.78 | 25.38 ± 0.54 | 0.45 |
| PCI or CABG History | 6 (22.2) | 2 (6.8) | 0.21 |
| CAD | |||
| Single Vessel Disease | 18 (66.7) | 19 (65.5) | |
| Two or Three Vessel Disease | 9 (33.3) | 10 (35.5) | 0.47 |
| Ejection Fraction, (%) | 46.11 ± 1.17 | 42.93 ± 1.60 | 0.13 |
| Hypertension | 8 (26.9) | 11 (37.9) | 0.34 |
| Medications | |||
| Statins, n | 27 | 29 | - |
| Aspirin, n | 27 | 29 | - |
| Plavix, n | 27 | 29 | - |
| β-Blocker, n | 25 | 29 | 0.30 |
| ACE-I / ARB, n | 27 | 29 | - |
Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; PCI, percutaneous coronary intervention.
aValues are expressed as mean ± SE or No. (%) of subjects for dichotomous measures.